Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
REMEGEN Spikes 14% as Innovative Drug Telitacicept Achieves Endpoint in Major Study
Recommend 4 Positive 9 Negative 1 |
||||
|
||||
|
REMEGEN (09995.HK) opened 4.7% higher today, and peaked at $79.5, setting a high in over 3.5 years. It last printed at $77.9, spiking 14.31%. Trading volume has increased to 15.5649 million shares, involving $1.17 billion. REMEGEN announced that the Phase III study of telitacicept, its independently developed BLyS/APRIL innovative dual-target fusion protein drug, for the treatment of primary Sjogren's syndrome achieved the primary endpoint in its clinical study. The clinical study results indicate that telitacicept can sustainably and effectively improve the clinical symptoms of patients with Sjogren's syndrome, demonstrating good efficacy and safety. The Company will promptly submit a launch application to the Center for Drug Reevaluation of the National Medical Products Administration (NMPA). AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
